. 2013 Jul 23;121(9):1040–1046. doi: 10.1289/ehp.1306734

Table 4.

Proliferative mammary gland lesions and tumors observed at PND90, PND140, and PND200 following either gestational only or gestational/lactational exposure to BPA.

Exposure group/BPA dose (μg/kg BW/day)	Incidence		Diagnosis (age)
Exposure group/BPA dose (μg/kg BW/day)	Total lesions	Cancer	Diagnosis (age)
Gestational
0	1/35	0/35	Microfibroadenoma^a (PND140)
0.25	1/31	1/31	Adenocarcinoma^b,c (PND200)
2.5	1/28	1/28	Adenocarcinoma^b,c (PND90)
25	0/23	0/23	NA
250	2/30	1/30	Lobular alveolar hyperplasia^a (PND90), adenocarcinoma^b,c (PND140)
Gestational/lactational
0	0/30	0/30	NA
0.25	1/27	0/27	Lobular alveolar hyperplasia^a (PND140)
2.5	2/30	1/30	Adenocarcinoma^b,c (PND140), fibroadenoma^a,c (PND200)
25	2/28	1/28	Lobular alveolar hyperplasia^a (PND90), adenocarcinoma^b,c (PND140)
250	0/33	0/33	NA
NA, not applicable (no lesion or tumor detected for diagnosis). Ratios indicate the number of animals with the lesion or tumor relative to the total number of animals per dose per exposure period for PND90, PND140, and PND200 combined. Differences in tumor incidence following treatment were compared with vehicle by chi-square test and found not to be significant. ^aBenign. ^bMalignant. ^cTumor.